Cargando…

Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study

BACKGROUND: Palbociclib combined with endocrine therapy has been approved as a front-line treatment for hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) advanced breast cancer (ABC). A key challenge remains to uncover biomarkers to identify those patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Xiying, Zheng, Yabing, Cao, Wenming, Shen, Xiabo, Li, Guangliang, Chen, Junqing, Huang, Yuan, Huang, Ping, Shi, Lei, Ye, Weiwu, Zou, Weibin, Lou, Caijin, Lei, Lei, Huang, Jian, Chen, Zhanhong, Wang, Xiaojia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106007/ https://www.ncbi.nlm.nih.gov/pubmed/33987405 http://dx.doi.org/10.21037/atm-21-1340

Ejemplares similares

Exploring the concepts and practices of advanced breast cancer treatment: a narrative review
por: Wang, Xiaojia, et al.
Publicado: (2021)

Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy
por: Huang, Ping, et al.
Publicado: (2016)

Bioinformatics identification of dysregulated microRNAs in triple negative breast cancer based on microRNA expression profiling
por: Chen, Junqing, et al.
Publicado: (2018)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

Everolimus‐containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study
por: Chen, Zhanhong, et al.
Publicado: (2019)

Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
por: Wang, Wei, et al.
Publicado: (2023)

The prognostic and predictive potential of Ki-67 in triple-negative breast cancer
por: Zhu, Xiuzhi, et al.
Publicado: (2020)

Effects of low-dose tamoxifen on breast cancer biomarkers Ki-67, estrogen and progesterone receptors
por: de Sousa, Juarez Antônio, et al.
Publicado: (2006)

Associations of Estrogen Receptor, Progesterone Receptor, Human Epidemic Growth Factor Receptor-2 and Ki-67 with Ultrasound Signs and Prognosis of Breast Cancer Patients
por: Zhao, Xingjuan, et al.
Publicado: (2021)

The CYP19 RS4646 Polymorphism IS Related to the Prognosis of Stage I–II and Operable Stage III Breast Cancer
por: Shao, Xiying, et al.
Publicado: (2015)

The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review
por: He, Libin, et al.
Publicado: (2022)

ADAMTS9-AS1 Constrains Breast Cancer Cell Invasion and Proliferation via Sequestering miR-301b-3p
por: Chen, Junqing, et al.
Publicado: (2021)

Expression and significance of Her2 and Ki-67 in gastric adenocarcinoma without distant metastasis: a cohort study
por: Wei, Zhijian, et al.
Publicado: (2020)

Breast liposarcoma with solitary metastasis to the pleura: A case report
por: Lei, Lei, et al.
Publicado: (2017)

Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China
por: Chen, Zhanhong, et al.
Publicado: (2022)

Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling
por: Chen, Zhanhong, et al.
Publicado: (2019)

Ki-67 gene expression
por: Uxa, Sigrid, et al.
Publicado: (2021)

Quantifying the Ki-67 Heterogeneity Profile in Prostate Cancer
por: Mesko, Shane, et al.
Publicado: (2013)

To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study
por: Zong, Yu, et al.
Publicado: (2014)

Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.
por: Clarke, R. B., et al.
Publicado: (1993)

Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer
por: Oh, Hannah, et al.
Publicado: (2016)

Association of Menopausal Status, Expression of Progesterone Receptor and Ki67 to the Clinical Response to Neoadjuvant Chemotherapy in Luminal Breast Cancer
por: Silva, Leonardo Roberto da, et al.
Publicado: (2019)

Quantum Dots-Based Quantitative and In Situ Multiple Imaging on Ki67 and Cytokeratin to Improve Ki67 Assessment in Breast Cancer
por: Yuan, Jing Ping, et al.
Publicado: (2015)

Prognostic Value of Ki67 in Patients with Stage 1–2 Endometrial Cancer: Validation of the Cut-off Value of Ki67 as a Predictive Factor
por: Jiang, Peng, et al.
Publicado: (2020)

Corrigendum: To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

Prognostic and predictive value of Ki-67 in triple-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2016)

The intrinsically disorderly story of Ki-67
por: Remnant, Lucy, et al.
Publicado: (2021)

Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer
por: Ding, Yuqin, et al.
Publicado: (2020)

Construction of an mRNA-miRNA-lncRNA network prognostic for triple-negative breast cancer
por: Huang, Yuan, et al.
Publicado: (2021)

Expression and Clinical Significance of Ki67 and SOX2 in Colorectal Cancer
por: Hu, Bo, et al.
Publicado: (2023)

Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies
por: Fasanella, S, et al.
Publicado: (2011)

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
por: Nielsen, Torsten O, et al.
Publicado: (2020)

Automated Ki-67 Quantification of Immunohistochemical Staining Image of Human Nasopharyngeal Carcinoma Xenografts
por: Shi, Peng, et al.
Publicado: (2016)

Ki67 and the apparent diffusion coefficient in postoperative prostate cancer with endocrine therapy
por: He, Jun, et al.
Publicado: (2023)

Radiomic prediction models for the level of Ki-67 and p53 in glioma
por: Sun, Xiaojun, et al.
Publicado: (2020)

The relationships of OSBPL3 expression with KI-67 expression and KRAS mutations in CRC: implications for diagnosis and prognosis
por: Zhang, Min, et al.
Publicado: (2022)

The expression of Ki-67 and Glypican -3 in hepatocellular carcinoma was evaluated by comparing DWI and (18)F-FDG PET/CT
por: Wang, Xuedong, et al.
Publicado: (2023)

Immunolocalization of Ki-67 in different periodontal conditions
por: Preethi, Penubolu Lakshmi, et al.
Publicado: (2014)

DNA topoisomerase IIα and Ki67 are prognostic factors in patients with hepatocellular carcinoma
por: Cao, Yi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pdo2aefpmeqavv8iqaqjkcpqfr